A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis.

Clin Transl Med · 2023 · PMC10644327 · PMID 37962000

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In summary, although the effects of selnoflast on the IL‐1 gene signature showed a trend in the right direction, the effect was rather modest compared with that of other therapeutic agents such as anti‐TNF or anti‐IL‐6 antibodies. 28 , 29 4.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.